Cargando…

A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study

BACKGROUND: CT-P13 (Remsima®, Inflectra®) is a biosimilar of the infliximab reference product (RP; Remicade®). The aim of this study was to compare the 54-week efficacy, immunogenicity, safety, pharmacokinetics (PK) and pharmacodynamics (PD) of CT-P13 and RP in patients with active rheumatoid arthri...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yoo, Dae Hyun, Racewicz, Artur, Brzezicki, Jan, Yatsyshyn, Roman, Arteaga, Edgardo Tobias, Baranauskaite, Asta, Abud-Mendoza, Carlos, Navarra, Sandra, Kadinov, Vladimir, Sariego, Irmgadt Goecke, Hong, Seung Suh, Lee, Sung Young, Park, Won
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4818886/ https://www.ncbi.nlm.nih.gov/pubmed/27038608 http://dx.doi.org/10.1186/s13075-016-0981-6

Ejemplares similares

Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study
por: Park, Won, et al.
Publicado: (2016)

Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study
por: Yoo, Dae Hyun, et al.
Publicado: (2017)

Comparing biosimilar SB2 with reference infliximab after 54 weeks of a double-blind trial: clinical, structural and safety results
por: Smolen, Josef S., et al.
Publicado: (2017)

A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy
por: Choe, Jung-Yoon, et al.
Publicado: (2017)

Switching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid Arthritis: Fifty‐Two–Week Phase III Randomized Study Results
por: Weinblatt, Michael E., et al.
Publicado: (2018)

A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study
por: Yoo, Dae Hyun, et al.
Publicado: (2013)

Safety, immunogenicity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis: results of a randomised, double-blind, phase III transition study
por: Smolen, Josef S, et al.
Publicado: (2018)

Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study
por: Park, Won, et al.
Publicado: (2017)

Randomised, double-blind, phase III study comparing the infliximab biosimilar, PF-06438179/GP1111, with reference infliximab: efficacy, safety and immunogenicity from week 30 to week 54
por: Alten, Rieke, et al.
Publicado: (2019)

Evaluation of the pharmacokinetic equivalence and 54-week efficacy and safety of CT-P13 and innovator infliximab in Japanese patients with rheumatoid arthritis
por: Takeuchi, Tsutomu, et al.
Publicado: (2015)

Septic serum induces glucocorticoid resistance and modifies the expression of glucocorticoid isoforms receptors: a prospective cohort study and in vitro experimental assay
por: Guerrero, Julia, et al.
Publicado: (2013)

Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study
por: Baranauskaite, Asta, et al.
Publicado: (2011)

A comparative study of PF‐06438179/GP1111 (an infliximab biosimilar) and reference infliximab in patients with moderate to severe active rheumatoid arthritis: A subgroup analysis
por: Kameda, Hideto, et al.
Publicado: (2020)

Manual de primeros auxilios y emergencias en perros y gatos /
por: Mendoza Sariego, María Luisa
Publicado: (2011)

Prevalencia y factores de riesgo de Cryptosporidium spp y Giardia spp. en perros y niños de edad preescolar en el municipio de Boca del Río, Veracruz, México /
por: Mendoza Sariego, Ma. Luisa
Publicado: (2015)

Cataract Surgery in Behçet's Disease Patients One Week after Infliximab Administration
por: Handa, Tsuneaki, et al.
Publicado: (2011)

Trabeculotomy in a Behçet's Disease Patient One Week after Infliximab Administration
por: Koike, Aya, et al.
Publicado: (2012)

74-week follow-up of safety of infliximab in patients with refractory rheumatoid arthritis
por: Delabaye, Isabelle, et al.
Publicado: (2010)

The impact of anti-cyclic citrullinated peptide antibody status on the management of patients with early rheumatoid arthritis: observational study results from Lithuania
por: Stropuvienė, Sigita, et al.
Publicado: (2018)

Nurse’s Role from Medical Students’ Perspective during Their Interprofessional Clinical Practice: Evidence from Lithuania
por: Blaževičienė, Aurelija, et al.
Publicado: (2021)

Clinical correlations of infliximab trough levels and antibodies to infliximab in South Korean patients with Crohn’s disease
por: Oh, Eun Hye, et al.
Publicado: (2017)

Infusion reaction to infliximab biosimilar after transitioning from infliximab
por: Kashlan, Reem, et al.
Publicado: (2020)

Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases
por: Ducourau, Emilie, et al.
Publicado: (2011)

Switching and Discontinuation Patterns Among Patients Stable on Originator Infliximab Who Switched to an Infliximab Biosimilar or Remained on Originator Infliximab
por: Fitzgerald, Timothy, et al.
Publicado: (2021)

Infliximab and biosimilar infliximab in psoriasis: efficacy, loss of efficacy, and adverse events
por: Subedi, Smriti, et al.
Publicado: (2019)

A randomized, double-blind, placebo-controlled 12-week trial of infliximab in patients with juvenile-onset spondyloarthritis
por: Burgos-Vargas, Rubén, et al.
Publicado: (2022)

Impact of Introducing Infliximab Biosimilars on Total Infliximab Consumption and Originator Infliximab Prices in Eight Regions: An Interrupted Time-Series Analysis
por: Peng, Kuan, et al.
Publicado: (2023)

Management Meeting No.54
por: Reich, K H
Publicado: (1961)

Infliximab in ulcerative colitis
por: Levin, Avi, et al.
Publicado: (2008)

The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease
por: Vande Casteele, Niels, et al.
Publicado: (2015)

Serum Levels of Infliximab and Anti-Infliximab Antibodies in Brazilian Patients with Crohn's Disease
por: Gomes, Luis Eduardo Miani, et al.
Publicado: (2019)

An optimal ultrasonographic diagnostic test for early gout: A prospective controlled study
por: Norkuviene, Eleonora, et al.
Publicado: (2017)

52-week results of the phase 3 randomized study comparing SB4 with reference etanercept in patients with active rheumatoid arthritis
por: Emery, Paul, et al.
Publicado: (2017)

Changes in the Intestinal Microbiota of Patients with Inflammatory Bowel Disease with Clinical Remission during an 8-Week Infliximab Infusion Cycle
por: Seong, Gyeol, et al.
Publicado: (2020)

Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate‐to‐Severe Rheumatoid Arthritis
por: Weinblatt, Michael E., et al.
Publicado: (2017)

Long-term Efficacy, Safety, and Immunogenicity of the Infliximab (IFX) Biosimilar, PF-06438179/GP1111, in Patients with Rheumatoid Arthritis After Switching from Reference IFX or Continuing Biosimilar Therapy: Week 54–78 Data From a Randomized, Double-Blind, Phase III Trial
por: Cohen, Stanley B., et al.
Publicado: (2020)

Low Dose Infliximab for Prevention of Postoperative Recurrence of Crohn’s Disease: Long Term Follow-Up and Impact of Infliximab Trough Levels and Antibodies to Infliximab
por: Sorrentino, Dario, et al.
Publicado: (2015)

Refractory Duodenal Crohn's Disease Successfully Treated with Infliximab
por: Kim, You Lim, et al.
Publicado: (2014)

Restless Legs Syndrome During Pregnancy and 12 Weeks Postpartum and Its Links to Cardiovascular Diseases, Stressful Life Events, and Psychiatric History
por: Goecke, Tamme W., et al.
Publicado: (2020)

54th INTC Meeting
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_pdkh9rf2tmvhbf3773fngk86g1